We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+30.25%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12B
AUM Growth
+$2.23B
Cap. Flow
-$2.3B
Cap. Flow %
-19.15%
Top 10 Hldgs %
76.74%
Holding
140
New
18
Increased
23
Reduced
51
Closed
10

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$121M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$106M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$76.4M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.5M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$34.6M

Top Sells

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$653M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$73M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$30.8M
4
PCYC
PHARMACYCLICS INC
PCYC
+$17.3M
5
XOMA
Xoma
XOMA
+$8.13M

Sector Composition

Rank Sector Weight
1 Healthcare 45.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DSCI
26
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$29.3M 0.24%
3,457,841
-79,296
-2% -$675K
PGNX
27
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$26M 0.22%
4,350,808
-98,989
-2% -$623K
ACGN
28
DELISTED
Aceragen Inc
ACGN
$25.8M 0.21%
51,268
+39,284
+328% +$24M
ALDR
29
DELISTED
Alder Biopharmaceuticals
ALDR
$25.4M 0.21%
879,581
+726,231
+474% +$19.9M
ACOR
30
DELISTED
Acorda Therapeutics
ACOR
$24.6M 0.2%
6,158
-138
-2% -$632K
GILD icon
31
Gilead Sciences
GILD
$181B
$24.5M 0.2%
249,995
-6,113
-2% -$621K
SGMO
32
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$22M 0.18%
1,404,544
+449,212
+47% +$6.95M
NBIX icon
33
Neurocrine Biosciences
NBIX
$15.5B
$21.5M 0.18%
542,236
-12,354
-2% -$442K
KYTH
34
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$17.8M 0.15%
354,265
+68,010
+24% +$2.85M
BLUE
35
DELISTED
bluebird bio
BLUE
$17.7M 0.15%
11,316
-264
-2% -$348K
RPRX
36
DELISTED
Repros Therapeutics Inc.
RPRX
$17.2M 0.14%
2,000,000
– –
FOMX
37
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$16.9M 0.14%
1,821,967
+800,367
+78% +$7.16M
VNDA icon
38
Vanda Pharmaceuticals
VNDA
$319M
$16.3M 0.14%
1,750,230
-2,721,923
-61% -$30.8M
NVAX icon
39
Novavax
NVAX
$1.47B
$16.1M 0.13%
97,284
+36,116
+59% +$5.86M
IOVA icon
40
Iovance Biotherapeutics
IOVA
$3.76B
$16M 0.13%
+1,325,000
New +$14.9M
CLVS
41
DELISTED
Clovis Oncology, Inc.
CLVS
$15M 0.13%
202,630
– –
AGIO icon
42
Agios Pharmaceuticals
AGIO
$1.98B
$14.1M 0.12%
149,954
-13,439
-8% -$1.51M
OMER icon
43
Omeros
OMER
$1.39B
$14M 0.12%
637,446
-10,655
-2% -$243K
XNCR icon
44
Xencor
XNCR
$2.07B
$13.4M 0.11%
872,072
+280,701
+47% +$4.43M
MTEM
45
DELISTED
Molecular Templates, Inc.
MTEM
$11.9M 0.1%
17,730
+4,666
+36% +$3.07M
ARCT icon
46
Arcturus Therapeutics
ARCT
$382M
$10.1M 0.08%
255,696
+214,286
+517% +$9.43M
NGNE icon
47
Neurogene
NGNE
$773M
$9.76M 0.08%
59,383
-1,135
-2% -$231K
MGNX icon
48
MacroGenics
MGNX
$261M
$9.57M 0.08%
305,043
-6,848
-2% -$232K
AERI
49
DELISTED
Aerie Pharmaceuticals
AERI
$9.38M 0.08%
299,356
– –
RARE icon
50
Ultragenyx Pharmaceutical
RARE
$2.55B
$9.24M 0.08%
148,894
-1,106
-0.7% -$61.4K
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2015 Portfolio in Review

As of Q1 2015, Julian Baker held 140 positions worth $12B, up 23% from $9.8B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Julian Baker withdrew a net $2.3B in Q1 2015, closing 10 positions and reducing 51 holdings. Its most notable exit was AVANIR PHARMACEUTICALS, INC CL A, an estimated $653M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 47% a quarter earlier.

Against the trend, Julian Baker opened a new position in Invitae Corporation worth $110M.

  • Julian Baker's largest Q1 2015 buy was Invitae Corporation: 6,554,967 shares worth $110M.
  • Julian Baker added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2015, an estimated $106M increase.
  • Julian Baker's biggest Q1 2015 reduction was Vanda Pharmaceuticals, cutting an estimated $30.8M.
  • Julian Baker fully exited AVANIR PHARMACEUTICALS, INC CL A in Q1 2015, selling an estimated $653M.
  • Julian Baker's ten largest holdings make up 77% of its $12B portfolio in Q1 2015.
  • Julian Baker opened 18 new positions and closed 10 in Q1 2015.
  • Julian Baker's portfolio value rose 23% quarter-over-quarter to $12B.

Based on Baker Bros. Advisors's 13F filing for Q1 2015, filed 15 May 2015.